vTv Therapeutics Company Profile (NASDAQ:VTVT)

About vTv Therapeutics (NASDAQ:VTVT)

vTv Therapeutics logovTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VTVT
  • CUSIP: N/A
  • Web: vtvtherapeutics.com/
Capitalization:
  • Market Cap: $71.53 million
  • Outstanding Shares: 9,693,000
Average Prices:
  • 50 Day Moving Avg: $6.30
  • 200 Day Moving Avg: $6.30
  • 52 Week Range: $3.57 - $8.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.28
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $119,000.00
  • Price / Sales: 601.13
  • Book Value: ($10.98) per share
  • Price / Book: -0.67
Profitability:
  • EBITDA: ($52,990,000.00)
  • Net Margins: -103,184.60%
  • Return on Assets: -127.94%
Debt:
  • Current Ratio: 2.95%
  • Quick Ratio: 2.95%
Misc:
  • Average Volume: 38,733 shs.
  • Beta: 0.9
  • Short Ratio: 9.39
 

Frequently Asked Questions for vTv Therapeutics (NASDAQ:VTVT)

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc (NASDAQ:VTVT) posted its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.41) EPS for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.02. The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.19 million. View vTv Therapeutics' Earnings History.

When will vTv Therapeutics make its next earnings announcement?

vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for vTv Therapeutics.

Where is vTv Therapeutics' stock going? Where will vTv Therapeutics' stock price be in 2017?

4 brokerages have issued twelve-month price objectives for vTv Therapeutics' shares. Their forecasts range from $13.00 to $24.00. On average, they anticipate vTv Therapeutics' share price to reach $16.50 in the next twelve months. View Analyst Ratings for vTv Therapeutics.

Who are some of vTv Therapeutics' key competitors?

Who are vTv Therapeutics' key executives?

vTv Therapeutics' management team includes the folowing people:

  • Jeffrey B. Kindler, Executive Chairman of the Board
  • Stephen L. Holcombe, President, Chief Executive Officer
  • Rudy C. Howard CPA, Chief Financial Officer, Executive Vice President
  • Larry Douglas Altstiel M.D. Ph.D., Chief Medical Officer
  • Steven M. Cohen, Director
  • Paul M. Meister, Director
  • Paul G. Savas, Director
  • Howard L. Weiner, Director
  • John A. Fry, Independent Director

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering (IPO) on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

Who owns vTv Therapeutics stock?

vTv Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include MACANDREWS & FORBES INC. (78.10%). Company insiders that own vTv Therapeutics stock include Noel Joseph Spiegel, Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics.

How do I buy vTv Therapeutics stock?

Shares of vTv Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is vTv Therapeutics' stock price today?

One share of vTv Therapeutics stock can currently be purchased for approximately $7.38.


MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  107 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for vTv Therapeutics (NASDAQ:VTVT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $16.50 (123.58% upside)
Consensus Price Target History for vTv Therapeutics (NASDAQ:VTVT)
Price Target History for vTv Therapeutics (NASDAQ:VTVT)
Analysts' Ratings History for vTv Therapeutics (NASDAQ:VTVT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Canaccord GenuityReiterated RatingBuy$15.00LowView Rating Details
8/4/2017HC WainwrightSet Price TargetBuy$13.00LowView Rating Details
3/30/2017Piper Jaffray CompaniesReiterated RatingOverweight$24.00LowView Rating Details
12/15/2016Stifel NicolausSet Price TargetBuy$14.00N/AView Rating Details
12/17/2015Janney Montgomery ScottInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 10/23/2015 forward)

Earnings

Earnings History for vTv Therapeutics (NASDAQ:VTVT)
Earnings by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Earnings History by Quarter for vTv Therapeutics (NASDAQ VTVT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017($0.42)N/AView Earnings Details
8/2/2017Q2 2017($0.43)($0.41)$0.19 million$0.01 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.44)($0.44)$0.20 million$0.03 millionViewN/AView Earnings Details
5/12/2016Q1($0.54)($0.42)$0.38 millionViewN/AView Earnings Details
3/1/2016Q4($0.47)($0.35)$0.03 million$0.23 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for vTv Therapeutics (NASDAQ:VTVT)
Current Year EPS Consensus Estimate: $-1.06 EPS
Next Year EPS Consensus Estimate: $-2.25 EPS

Dividends

Dividend History for vTv Therapeutics (NASDAQ:VTVT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for vTv Therapeutics (NASDAQ:VTVT)
Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 11.05%
Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Institutional Ownership by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Insider Trades by Quarter for vTv Therapeutics (NASDAQ:VTVT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2017Ronald O PerelmanMajor ShareholderBuy20,000$4.57$91,400.00View SEC Filing  
8/16/2017Ronald O PerelmanMajor ShareholderBuy10,000$4.97$49,700.00View SEC Filing  
8/15/2017Ronald O PerelmanMajor ShareholderBuy50,000$4.72$236,000.00View SEC Filing  
8/11/2017Ronald O PerelmanMajor ShareholderBuy85,000$4.13$351,050.00View SEC Filing  
5/15/2017Paul G SavasDirectorBuy3,000$5.18$15,540.00View SEC Filing  
3/31/2017Paul G SavasDirectorBuy10,000$6.50$65,000.00View SEC Filing  
5/27/2016Paul G SavasDirectorBuy6,000$5.67$34,020.00View SEC Filing  
5/24/2016Paul G SavasDirectorBuy1,259$5.26$6,622.34View SEC Filing  
4/8/2016Ronald O PerelmanMajor ShareholderBuy10,000$4.99$49,900.00View SEC Filing  
4/5/2016Ronald O PerelmanMajor ShareholderBuy400,000$5.20$2,080,000.00View SEC Filing  
3/28/2016Paul G SavasDirectorBuy10,000$5.35$53,500.00View SEC Filing  
3/24/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.64$56,400.00View SEC Filing  
3/7/2016Paul G SavasDirectorBuy15,000$5.82$87,300.00View SEC Filing  
2/12/2016Ronald O PerelmanMajor ShareholderBuy10,000$5.83$58,300.00View SEC Filing  
2/5/2016Ronald O PerelmanMajor ShareholderBuy10,000$6.43$64,300.00View SEC Filing  
2/4/2016Ronald O PerelmanMajor ShareholderBuy20,000$6.05$121,000.00View SEC Filing  
1/13/2016Ronald O PerelmanMajor ShareholderBuy15,000$6.41$96,150.00View SEC Filing  
12/18/2015Ronald O PerelmanMajor ShareholderBuy15,000$6.40$96,000.00View SEC Filing  
12/15/2015Noel Joseph SpiegelDirectorBuy5,710$6.20$35,402.00View SEC Filing  
10/2/2015Ronald O PerelmanMajor ShareholderBuy30,000$6.26$187,800.00View SEC Filing  
9/28/2015Ronald O PerelmanMajor ShareholderBuy40,000$6.04$241,600.00View SEC Filing  
9/25/2015Paul G SavasDirectorBuy5,000$6.62$33,100.00View SEC Filing  
9/22/2015Ronald O PerelmanMajor ShareholderBuy24,000$6.82$163,680.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for vTv Therapeutics (NASDAQ:VTVT)
Latest Headlines for vTv Therapeutics (NASDAQ:VTVT)
Source:
Loading headlines, please wait.

Social

Chart

vTv Therapeutics (VTVT) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.